drugset / Trial / NCT01991678
A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the PK and safety of NKTR-102 in patients with mild, moderate, or severe hepatic impairment.
Timeline
- Start
- 2013-11
- Primary completion
- 2017-05
- Completion
- 2017-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etirinotecan Pegol | Other / unclassified | 50 mg/m2 | Intravenous |
| Subject | Etirinotecan Pegol | Other / unclassified | 120 mg/m2 | Intravenous |
| Subject | Etirinotecan Pegol | Other / unclassified | 145 mg/m2 | Intravenous |
Indications
No indication recorded.